Global Multiplex Assays Market Overview:
According to SPER Market Research, the Multiplex Assays Market estimated to reach USD 5.6 billion by 2030 with a CAGR of 7.2%. The rising prevalence of chronic disorders require advanced diagnostic tools and testing methods for early detection and better treatment.
Impact of COVID-19 on the Multiple Assays Market
Multiplex assay market has grown significantly during the COVID-19 pandemic. Multiplex assays have been utilized for the diagnosis of SARS-CoV-2. The regulatory approvals were also relaxed to fasten the manufacturing and availability in the market to meet elevated demand. Temporary operational challenges were observed due to lockdowns. Overall, a positive impact is being observed with relaxation in travelling restrictions and rising demand for diagnosis purpose.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Product & Service, By Type, By Technology, By Application, By End User |
| Geographies covered | North America, Europe, APAC, Latin America and the Middle East & Africa |
| Companies Covered | Abcam Plc, Agilent Technologies, Inc., Antigenix America, Inc., AYOXXA Biosystems GmbH, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Boster Biological Technology, Cayman Chemical Company, DiaSorin S.p.A., Enzo Life Sciences, Inc., Illumina, Inc, Luminex Corporation, Merck KGaA, Meso Scale Diagnostics Olink, PerkinElmer, Inc., Promega Corporation, Qiagen N.V., Quanterix, Randox Laboratories, Seegene, Shimadzu Biotech, Siemens Healthineers, Thermo Fisher Scientific Inc. |
Driver: Rising use of multiplex assays
The use of multiplex assays is rising due to the increasing prevalence of chronic diseases and advantages offered by multiplex assays over singleplex assays. Multiplex assays provide faster delivery of diagnostic results and detection at lower concentration of reagents and analytes as compared to traditional and singleplex assays.
Restraint: High equipment cost and stringent regulatory framework
The equipment utilized in the manufacturing of multiplex assays are expensive which creates challenges to provide multiplex assay testing at an affordable cost. Additionally, the standards for Quality control are more stringent for multiplex assays in comparison to singleplex assays.
Opportunity: Rising validation of biomarkers
The validation of biomarkers is increasing in protein and molecular diagnostics. The technological advancements in multiplex assay testing instruments will increase efficiency and accuracy of the results which will create growth opportunities for multiplex assay market in the diagnosis of neurodegenerative disorders, cancer and autoimmune diseases.
Challenge: Lack of skilled technicians
There is a lack of skilled technicians who can handle multiplex assay instruments. This can pose a challenge to the growth of this market.
Multiple Assays Market Segmentation:
By Product & Service: Based on product and service, market has been segmented into Consumables, Instruments, Software & Service
By Type: Based on type, market has been segmented into Protein Multiplex Assays (Planar Protein Assays, Bead-Based Protein Assays, Other Protein Assays), Nucleic Acid Multiplex Assays (Planar Nucleic Acid Assays, Bead-Based Nucleic Acid Assays, Other Nucleic Acid Assays), Cell-Based Multiplex Assays
By Technology: Based on technology, market has been segmented into Flow Cytometry, Fluorescence Detection, Luminescence, Multiplex Real-Time PCR, Other Technologies
By Application: Based on application, market has been segmented into Research & Development (Drug Discovery & Development, Biomarker Discovery & Validation), Clinical Diagnostics (Infectious Diseases, Cancer, Cardiovascular Diseases, Autoimmune Diseases, Nervous System Disorders, Metabolism & Endocrinology Disorders, Other Diseases
By End User: Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Hospitals & Research Institutes, Reference Laboratories, Other End Users Pharmaceutical & biotechnology companies have the largest share of this market by end user due to rising adoption of multiplex assay testing in drug development process and rising focus on monoclonal antibodies & biosimilar products.
By Region: North America owns the largest share of this market due to factors such as presence of strong pharmaceutical industry, high Research and Development investment, technological advancement and growing biotechnology companies.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact of the Multiplex Assays Market
4.4. Market Trends
5. Global Multiplex Assays Market, By Product & Service, 2019-2030 (USD Million)
5.1. Consumables
5.2. Instruments
5.3. Software and Service
6. Global Multiplex Assays Market, By Type, 2019-2030 (USD Million)
6.1. Protein Multiplex Assays
6.1.1. Planar Protein Assays
6.1.2. Bead-Based Protein Assays
6.1.3. Other Protein Assays
6.2. Nucleic Acid Multiplex Assays
6.2.1. Planar Nucleic Acid Assays
6.2.2. Bead-Based Nucleic Acid Assays
6.2.3. Other Nucleic Acid Assays
6.3. Cell-Based Multiplex Assays
7. Global Multiplex Assays Market, By Technology, 2019-2030 (USD Million)
7.1. Flow Cytometry
7.2. Fluorescence Detection
7.3. Luminescence
7.4. Multiplex Real-Time PCR
7.5. Other Technologies
8. Global Multiplex Assays Market, By Application, 2019-2030 (USD Million)
8.1. Research & Development
8.1.1. Drug Discovery & Development
8.1.2. Biomarker Discovery & Validation
8.2. Clinical Diagnostics
8.2.1. Infectious Diseases
8.2.2. Cancer
8.2.3. Cardiovascular Diseases
8.2.4. Autoimmune Diseases
8.2.5. Nervous System Disorders
8.2.6. Metabolism & Endocrinology Disorders
8.2.7. Other Diseases
9. Global Multiplex Assays Market, By End User, 2019-2030 (USD Million)
9.1. Pharmaceutical & Biotechnology Companies
9.2. Hospitals & Research Institutes
9.3. Reference Laboratories
9.4. Other End Users
10. Global Multiplex Assays Market, By Geography, 2019-2030 (USD Million)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Italy
10.2.5. Spain
10.2.6. Rest of Europe
10.3. Asia-Pacific
10.3.1. China
10.3.2. Japan
10.3.3. India
10.3.4. Rest of Asia-Pacific
10.4. Rest of the World
10.4.1. Latin America
10.4.2. Middle East & Africa
11. Competitive Landscape
11.1. Introduction
11.2. Market Share Analysis, By Key Players
11.3. Competitive Scenario
11.3.1. Product Launches
11.3.2. Partnerships, Collaborations and Agreements
11.3.3. Acquisitions
11.3.4. Expansions
11.3.5. Other Developments
12. Company Profiles
12.1. Abcam Plc
12.2. Agilent Technologies, Inc.
12.3. Antigenix America, Inc.
12.4. AYOXXA Biosystems GmbH
12.5. Becton, Dickinson and Company
12.6. Bio-Rad Laboratories, Inc.
12.7. Bio-Techne Corporation
12.8. Boster Biological Technology
12.9. Cayman Chemical Company
12.10. DiaSorin S.p.A.
12.11. Enzo Life Sciences, Inc.
12.12. Illumina, Inc
12.13. Luminex Corporation
12.14. Merck KGaA
12.15. Meso Scale Diagnostics
12.16. Olink
12.17. PerkinElmer, Inc.
12.18. Promega Corporation
12.19. Qiagen N.V.
12.20. Quanterix
12.21. Randox Laboratories
12.22. Seegene
12.23. Shimadzu Biotech
12.24. Siemens Healthineers
12.25. Thermo Fisher Scientific Inc.
13. Appendix